CTLA4 and neoplasm: Similarly, in another study, we achieved prolonged survival in the same tumor model using a combination of a RASG12C(ON) inhibitor and Src homology region 2 domain-containing phosphatase-2 (SHP-2) inhibition with anti–PD-1 and anti–CTLA-4 (38).